Kelun-Biotech says Phase III sac-TMT plus Keytruda trial met PFS endpoint in PD-L1-negative NSCLC

OptiTROP-Lung06 showed statistically significant and clinically meaningful progression-free survival improvement versus pembrolizumab plus pemetrexed and platinum chemotherapy, with a positive overall survival trend at interim analysis.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.